Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to the Accelerated Approval Program. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
2026 · 2nd Quarter (Apr 1 - June 30)
PTC THERAPEUTICS, INC.
Filed by LMH STRATEGIC SOLUTIONS.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 5, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- LMH STRATEGIC SOLUTIONS
- Client
- PTC THERAPEUTICS, INC.
- Filing UUID
- 49fbff0d-5cef-4ee3-9748-3097888759af
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.